Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone? - Takeaways - MDSpire

Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?

  • By

  • Rus Prelog, Polona

  • Zupan, Matija

  • Kovacic, Alenka

  • Frol, Senta

  • Gregoric Kramberger, Milica

  • May 4, 2026

  • 0 min

Share

  • 1

    Approximately 2.2 million in the US and 5.9 million in the EU may qualify for amyloid-targeting treatment for Alzheimer's disease.

  • 2

    Amyloid-related imaging abnormalities (ARIAs) can occur as edema or hemorrhage, posing risks for patients receiving amyloid-targeting therapy.

  • 3

    Patients with bleeding disorders or cerebrovascular comorbidities were excluded from major trials of amyloid-targeting therapies due to increased ARIA risk.

  • 4

    Concomitant use of antiplatelet medications may heighten the risk of ARIA-H in Alzheimer's patients treated with amyloid-targeting therapies.

  • 5

    Psychiatric medications, particularly SSRIs, can increase bleeding risk in Alzheimer's patients, complicating treatment with amyloid-targeting therapies.

Original Source(s)

Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?

  • by Rus Prelog, Polona , Zupan, Matija , Kovacic, Alenka , Frol, Senta , Gregoric Kramberger, Milica

  • May 4, 2026

Related Content

Associations of Individual- and Neighborhood-Level Factors with Racial and Ethnic Disparities in Timely Dementia Diagnosis

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Home Health Value-Based Purchasing and Postacute Home Health Visits Among Older Adults With Dementia